Dow Chemical's president and chief operating officer Andrew Liveris has been appointed chief executive of the company, replacing William Stavropoulos who remains chairman. Liveris joined Dow in 1976 and has served in manufacturing, sales, marketing, new business development and management positions.
Israel's Teva Pharmaceutical Industries has named William Fletcher chairman of Teva North America from 1 January 2005. George Barrett will replace Fletcher as president and CEO of Teva North America and was also named Teva group vice president. He will be replaced in his roles at Teva Pharma USA by William Marth, who is currently executive vice president at the company's US unit. Meanwhile, Marvin Samson has been appointed group vice president for injectables while Amir Elstein will take over as group vice president for biogenerics.
Mark Bulriss, chairman and CEO of Great Lakes Chemical, has resigned his position for personal reasons. The company has appointed non-executive chairman and chief financial officer John Gallagher as interim CEO until a new CEO is identified. The current vice president for financial planning and investor relations, Jeffrey Potrzebowski, has been appointed acting CFO.
Mitsuo Ohashi has resigned as president and CEO of Japanese chemical company Showa Denko in order to become representative director and chairman. The company has appointed senior managing director Kyohei Takahashi as his replacement, effective 4 January, 2005. The management changes are part of a wider strategic reorganisation of the company.
Graham Corp, a specialist in vacuum and heat transfer equipment for the process industries, has appointed William Johnson as its new president and CEO. Johnson replaces retiring president and CEO Alvaro Cadena.
Alpharma's director of US sales for its active pharmaceutical business, Patrick Vazquez, has been appointed President of the US-based Drug Chemical and Associated Technologies Association (DCAT).
Transdermal drug delivery company Noven Pharmaceuticals has named pharmaceutical industry veteran Pedro Granadillo to its board of directors. He was formerly at Eli Lilly for 35 years, most recently as senior vice president, global manufacturing and human resources.